NASDAQ
Gilead Sciences, Inc. (GILD)
♥ 606 Thanks from members
Gilead Sciences faces a divergence between robust commercial growth, driven by a 10% revenue acceleration and HIV portfolio gains, and a massive GAAP loss caused by $11 billion in IPR&D charges from strategic acquisitions.